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Severe combined immunodeficiencies (SCIDs) are a group of inborn errors of the
immune system, usually associated with severe or life-threatening infections. Due to
the variability of clinical phenotypes, the diagnostic complexity and the heterogeneity
of the genetic basis, they are often difficult to recognize, leading to a significant
diagnostic delay (DD). Aim of this study is to define presenting signs and natural
history of SCID in a large cohort of patients, prior to hematopoietic stem cell or gene
therapies. To this purpose, we conducted a 30-year retro-prospective multicenter study
within the Italian Primary Immunodeficiency Network. One hundred eleven patients,
diagnosed as typical or atypical SCID according to the European Society for Immune
Deficiencies criteria, were included. Patients were subsequently classified based on the
genetic alteration, pathogenic mechanism and immunological classification. A positive
relationship between the age at onset and the DD was found. SCID patients with
later onset were identified only in the last decade of observation. Syndromic SCIDs
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represented 28% of the cohort. Eight percent of the subjects were diagnosed in Intensive
Care Units. Fifty-three percent had an atypical phenotype and most of them exhibited a
discordant genotype-immunophenotype. Pre-treatment mortality was higher in atypical
and syndromic patients. Our study broadens the knowledge of clinical and laboratory
manifestations and genotype/phenotype correlation in patients with SCID and may
facilitate the diagnosis of both typical and atypical forms of the disease in countries where
newborn screening programs have not yet been implemented.
Keywords: primary immunodeficiencies, severe combined immunodeficiencies, atypical SCID, T-cell defects,
lymphopenia, Omenn syndrome, maternal engraftment, next generation sequencing
INTRODUCTION
Severe combined immunodeficiencies (SCIDs) are a large group
of rare primary disorders due to defects in different genes
involved in T- and often B- and NK- cell development or
function, resulting in severe and sometimes life-threatening
infections (1). The phenotypic complexity and heterogeneity of
SCIDs may complicate the diagnosis thus frequently leading to
a significant diagnostic delay (DD). To date, population-based
newborn screening (NBS) represent the best strategy for the early
identification of affected newborns prior to the onset of infections
and other complications. The introduction of the NBS programs
revealed that the prevalence of the disorder is much higher than
the previously reported, accounting for 1:58,000 newborns, or
even 1:7,300 live births, if other forms of T-cell lymphopenia
are included (2, 3). However, it should be noted that NBS may
fail to detect some CIDs, i.e., ZAP70, ORAI1, or MHC class
II deficiencies, or SCIDs due to hypomorphic mutations, since
in these cases thymic output may not be dramatically affected.
Moreover, it is currently available in few Countries. For this
reason, improving the awareness of the clinical and laboratory
signs at presentation and the natural history may be particularly
important to achieve a timely diagnosis (4–7).
Typically, SCID patients who have absent T cells can be
further classified on the basis of the absence or presence of B
and NK cells. To date, according to the International Union
of Immunological Societies 17 different genes are recognized
as responsible for T−B+ or T−B− SCIDs. However, this
number will progressively increase over the next few years (8–
10), thanks to the availability of new high-throughput deep
sequencing analysis. Thanks to this technology, different new
SCID related genes, such as EXTL3, BCL11B, DOCK2, LAT,
ARPC1B have been recently identified (11–15). The introduction
of next generation sequencing in the clinical practice also
allowed to identify new clinical phenotypes associated with well-
known genetic defects, making more difficult the recognition
of these conditions (16). SCID patients may often exhibit
extra-immunological manifestations, which may even represent
the dominant clinical phenotype at presentation, masking the
underlying immunodeficiency. Hypomorphic mutations in some
known SCID-causing genes may result in atypical presenting
phenotypes, mainly characterized by immunodysregulation with
a less remarkable increase of the susceptibility to infections.
Eventually, a better definition of the clinical signs in patients
with more severe forms compared to those with milder
phenotypes, deserves careful attention for the implication in the
overall management.
Finally, a better understanding of the clinical variability
associated with the same gene defect, even within the same
family, may help recognize patients (17) and unravel the
complexity of the pathogenesis also in these well-established
monogenic disorders.
The aim of the present study is to describe the clinical,
immunologic and genetic features of a cohort of Italian patients
affected with SCID identified within the activity of the Italian
Primary Immunodeficiency Network (IPINET), with a special
focus on the presenting signs and on the natural history prior to
definitive therapeutic interventions.
MATERIALS AND METHODS
Patient Source and Enrollment
This is a retrospective and prospective multicenter longitudinal
clinical study involving patients with SCID identified by IPINET
Centers. The primary aim of the study is to better define
the presenting signs and the clinical history of these complex
disorders prior to hematopoietic stem cell (HSCT) or gene
therapies (GT).
Patients who received a diagnosis of typical or atypical SCID
between January 1, 1986 and December 31, 2017, were included
in the study, after written informed consent had been obtained
from the participants and parents/legal guardians. Patients
identified through NBS program, currently available only in
Tuscany and Campania, have been excluded. Eligibility was
verified by the principal investigator on the basis of inclusion
and exclusion criteria. Typical SCID was defined according to
the European Society for Immunodeficiencies (ESID) criteria
in patients with: (1) mutation(s) in a gene associated with a
typical SCID phenotype; or, (2) presentation with severe or
opportunistic infections, persistent diarrhea and failure to thrive,
in the presence of low (300/µl) or absent CD3+ or CD4+ or
CD8+ T cells, reduced naive CD4+ (CD3+CD4+CD45RA+)
and/or CD8+ (CD3+CD8+CD45RA+) T cells, elevated γδ T
cells, absence of proliferative responses to mitogens, defined
as proliferative response to phytohemagglutinin (PHA) lower
than 10% of the control subject; or (3) T cells of maternal
origin present. However, differently from ESID criteria, we also
included patients with onset after the first year of life when the
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other criteria were fulfilled. Atypical SCIDs were characterized by
CD3+ > 300 cells/µl and reduced, but detectable, proliferative
response to PHA (> 10 < 30% of the control). In order to
avoid the inclusion of patients with milder forms, as combined
immunodeficiency (CID), only atypical SCID younger than 2
years of age, were included. The following reference values were
used to characterize the immune phenotype: B+ (B-cell count
> 400 mm3), Blow (50 to 400 mm3), or B− (< 50 mm3) and
natural killer (NK)+ (NK-cell count > 100 mm3), NKlow (40
to 100 mm3), or NK− (< 40 mm3) according to Pai et al. (10)
Omenn syndrome (OS) was defined in presence of desquamating
erythroderma, absence of maternal engraftment (ME), absent or
low (< 30% of normal) T-cell proliferation, low naïve cells, and at
least 1 of the following supportive criteria: hepato-splenomegaly,
lymphadenopathy, failure to thrive, chronic diarrhea, increased
IgE level or absolute eosinophil count, and peripheral expansion
of self-reactive oligoclonal T cells (18). Different techniques were
used to detect ME, including cytogenetics (XX/XY chimerism
assay by FISH in male subjects, n = 3), restriction fragment
length polymorphism analysis (RFLP, n = 3) in patients
diagnosed before 2006, short tandem repeat analysis (STR,
n = 34) or HLA high resolution typing (n = 13) for patients
diagnosed in the third decade of observation. In all the cases, the
analysis was performed on PBMCs. ME was considered unlikely
if CD3+ T cells were undetectable (< 100 cells/mm3) or very low
(> 100 and < 300 cells/mm3) in patients with no clinical signs of
ME and no analysis was performed in these cases. In addition,
patients with known genetic defect were grouped according to
the main pathway implicated as follows: Metabolic Disorders
(MD), due to inherited disorders of the purine metabolism,
such as Adenosine Deaminase (ADA) deficiency; Cytokine
Signaling Defects (CSD), whose prototype was X-Linked
SCID due to mutations in the interleukin 2 receptor gamma
(IL2RG) gene, a component of several cytokine receptors; V(D)J
Recombination Disorders (VDJ), mainly caused by mutations
in the recombination activating genes (RAG) 1 and 2; DNA
Repair Defects (DNA-RD), due to alterations in genes involved
in preserving genomic stability; Thymic Disorders (TD), due to
abnormalities of the stromal component of the thymus. Patients
with secondary immunodeficiencies, with other well-defined
PIDs such as Ataxia-Telangiectasia, Hyper-IgE syndrome,
Wiskott-Aldrich syndrome, Dyskeratosis congenital and/or
incomplete diagnostic criteria were excluded. Age at Onset (AO)
was defined as the age at the first documented SCID-related
symptoms, Age at Diagnosis (AD) as the age at diagnosis of
SCID, while Diagnostic Delay (DD) was defined as the difference
between the two values. Patients were defined syndromic if they
showed at least 2 non-immunological symptoms such as: peculiar
facial dysmorphic features, microcephaly, cognitive impairment,
ectodermal abnormalities, renal defects, or gut abnormalities.
The number of signs was calculated taking into account the
number of events indicated by the Referents of the participating
Centers for each category. Categories analyzed were: infectious
diseases, including bacterial, viral, or opportunistic infections of
respiratory tract, central nervous system (CNS), skin and lymph
node, gastrointestinal and muscolo-skeletal system, systemic
sepsis; gastrointestinal manifestations, including chronic
diarrhea, failure to thrive; eczema; manifestation due to immune
dysregulation as autoimmune cytopenia, granuloma, ectodermal
disorders, vasculitis, thyroiditis; hematological disorders
including hemophagocytic lymphohistiocytosis, systemic or
localized lymphadenopathy, lymphoproliferative disorders.
Organomegaly, ME and OS were also taken in consideration. We
counted only once each clinical sign within the category. The
study, conducted according to the World Medical Association
Declaration of Helsinki ethical principle, was approved by
the Coordinator Center Ethics Committee (Federico II Ethics
Committee, registration number 61/17) and further approved by
local Ethics Committees of all participating groups. Complete
immunological characterization was available for 99 (89%)
patients. Genetic analyses were performed in 88 (79%) patients,
since the molecular characterization was very limited in the 80’s
and only recently deep sequencing technologies have been widely
introduced into the clinical practice. All laboratory results,
including complete blood count, were analyzed with reference to
age-related normal ranges.
Statistical Analysis
Data were shown as mean ± SD, median and range, or
frequencies (number of cases) and percentages as appropriate.
Student’s t-test was used to compare means for continuous
variables. Chi-square test or Fisher’s exact test were used
for categorical variables. Comparisons between groups were
performed using the non-parametric Mann-Whitney test for
quantitative variables. All P-values are two-sided and values <
0.05 were considered significant. Furthermore, we performed a
hypothesis-free multivariate analysis, using factor analysis. This
method divides total data variability into components to explain
the largest amount of variability in the data. A scree plot was used
to select the appropriate number of components for evaluation.
A factor loading size of 0.7 or greater indicates that a variable
was associated with that component. Varimax rotation was used
to enable a clearer interpretation of the results. Variables with a
highly skewed distribution were analyzed on the log scale. The
calculations were performed using IBM SPSS Statistics, v.20.0
software (IBM Corp. Armonk, NY).
RESULTS
Demographic Features
Table 1 summarizes the demographic data. The cohort included
111 patients (56.7% males). Most of the patients (n= 86) were of
Italian origin, while the remaining 22.6% (n= 25) of the subjects
were of a different geographic origin. Ninety-four percent of
them were diagnosed based on the clinical history and presenting
signs. Prenatal or pre-symptomatic investigations in families with
other affected babies, led to the diagnosis of SCID in 1 (0.9%) and
5 (4.5%) cases, respectively. A familial history suggestive of SCID,
including early infant deaths or other PIDs signs was reported in
23.3% of cases. Thirty-three percent of the infants were referred
to an IPINET Center before the 3rd month of life, while 22.5%
of the patients were referred after 1 year of life. A significant
proportion of patients (28%) had a syndromic phenotype with
more than two non-immunological features. Most of the patients
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TABLE 1 | Demographic features of the SCID cohort.
Total (n = 111) Non-syndromic (n = 80) Syndromic (n = 31)
N total Percent cases N total Percent cases N total Percent cases
Gender
Male 63 56.7 52 65 11 35.5
Female 48 43.3 28 35 20 64.5
Country of origin
Italy 86 77.4 58 72.5 28 90.3
North-Africa 5 4.5 3 3.7 2 6.4
Tunisia 1 0.9 1 1.25 0 0
Morocco 2 1.8 1 1.25 1 3.2
Senegal 1 0.9 1 1.25 0 0
Lybia 1 0.9 0 0 1 3.2
USA/South America 3 2.7 2 2.5 1 3.2
Asia 7 6.3 7 8.7 0 0
Saudi Arabia 1 0.9
Iran 1 0.9
Lebanon 2 1.8
India 1 0.9
Turkey 1 0.9
Pakistan 1 0.9
Eastern Europe 8 7.2 8 7.2 0 0
Romania 5 4.5
Serbia 1 0.9
Macedonia 2 1.8
Northern Europe 2 1.8 2 2.6 0 0
Netherland 1 0.9
Belgium 1 0.9
Positive family history
SCID 16 14.9 9 11.25 7 22.6
Other PIDs 3 2.8 1 1.25 2 6.4
Early infant death 6 5.6 2 2.5 4 13
(62.7%) were diagnosed in the last decade (2006–2016), while
only the 15.5% were diagnosed in the first decade (1986–1995)
(Figure 1A). The proportion of typical and atypical SCIDs was
similar across the entire period of observation.
As shown in Figure 1B, a considerable increase of early
diagnoses (< 3 months of age) was noted in the last decade
of observation and almost all late onset forms (> 9 months)
were diagnosed in the last decade of observation. Within the
early onset group (AO ≤ 9 months), the median AO of the
disease was 2 months (range 0–9 months), while in the late onset
group (AO > 9 months) it was 13 months (range 10–36 months)
(P < 0.0001). Sixty-nine out of 111 pts (62%), whose AO was
within the first 6 month of life, received a diagnosis by the 7th
month of life (Figure 1C). As shown in the Figure 1, there was
a significant direct correlation between AD and diagnostic delay
(DD) (Figure 1D). AO was lower in patients with MD compared
to CSD (p = 0.045) and in those with TD compared to DNA-RD
(p = 0.034) (Figure 1E). DD was higher in patients with DNA-
RD (median 18 months), even though the difference was not
statistically significant (Figure 1F).
Characteristics of the Infants at Diagnosis
Table 2 summarizes the clinical features of the cohort. Almost
all the subjects (95.5%) were symptomatic at diagnosis. In
particular, 91 patients had 4 or more clinical signs at the
diagnosis, including severe or persistent infections and/or
immunedysregulation, while 13 patients had more than 10
signs. Most of the patients with atypical SCID had more than
10 signs (Supplemental Figure 1). Infections were documented
at diagnosis in 94 of the 111 children (85%). The most
common manifestations of infections were: lobar and/or
interstitial pneumonia (54%), otitis (18%), bronchiolitis (16%),
and sepsis (9%). Thirteen percent of pneumonia were interstitial
pneumonia due to Pneumocystis Jiroveci confirmed by positive
microscopy, while 22% were of undetermined origin. Meningitis
was documented only in 3 patients (3%). Other infectious
manifestations included severe/systemic viral infections (28%),
and were due to CMV (16%), EBV (6%), HSV (4.5%), and
adenovirus (1%). Other opportunistic or BCG/mycobacterial
infections were documented in 22 and 5% of the patients,
respectively. Five patients who had BCG infection came from
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FIGURE 1 | Patients’ demographics. (A) Number of typical or atypical SCID patients diagnosed during the overall study period. (B) Histogram distribution of patients
grouped by age at onset. (C) Correlation between age at onset and age at diagnosis, and (D) between age at diagnosis and diagnostic delay. Filled circles indicate
groups of SCID patients (between 2 and 5) with same values. (E) Age at onset and (F) diagnostic delay (median) for the various pathogenic group of SCID. MD,
Metabolic Disorders; CSD, Cytokine Signaling Disorders; VDJ, VDJ abnormalities; TD, Thymic Disorders; DNA-RD, DNA Repair Disorders.
Countries where BCG vaccine is administered. Interestingly, 9
previously healthy children presented with a severe infection
rapidly worsening and requiring admission to intensive care
unit (ICU) (8.1%). OS was found in 19 subjects (18%). Thirty-
four percent of the 53 patients analyzed were positive for ME.
In 3 of the 18 subjects with ME, a fully expressed Omenn-
like disease, characterized by erythrodermia or severe eczema,
alopecia, hepatosplenomegaly, and eosinophilia, was observed.
Gastrointestinal disorders were detected in 49% of the
children, failure to thrive being the most frequent clinical
manifestation (35%). Chronic diarrhea was reported in 24% of
cases. Severe protein-losing enteropathy and villous atrophy were
reported in 6 patients (5%).
The most common dermatological alteration was eczema,
present in 24% of the patients. Four percent showed a localized
easy-to-treat dermatitis, 9% a moderate-diffuse form and 12%
erythroderma or a severe, diffuse, difficult-to-treat eczema. Other
dermatological disorders included alopecia and/or ectodermal
abnormalities, as detailed in the Table 2.
Overall, 25 patients (22%) showed signs of immune
dysregulation at the initial clinical and functional evaluation.
Among these, 13 had autoimmune cytopenia, 3 presented with
granulomatous disease, and 2 had thyroiditis or vasculitis.
Hematological disorders were reported in 17 patients
(15%), including HLH in 4 cases, localized or systemic
lymphadenopathy in 13, and lymphoproliferative disorders in
2 of them. Failure to thrive, villous atrophy, meningitis or
other severe bacterial infections, immunedysregulation and
erythroderma were significantly more frequent in syndromic
vs. non syndromic patients and in atypical vs. typical SCID
groups, as shown in the Table 2 and in Supplemental Table S1.
On the contrary, severe systemic viral infections, OS, eczema
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TABLE 2 | Clinical features of patients at diagnosis.
Feature Overall (%) Non-syndromic (%) Syndromic (%) P-value
No = 111 No = 80 No = 31
Infections (N) 94 (85) 65 (76) 29 (93.5) 0.147
Major respiratory tract infections 75 (67) 51 (64) 24 (77) 0.356
Pneumonia 65 (54) 44 (55) 21 (68) 0.389
Lobar 26 (23) 20 (25) 6 (19) 0.528
Interstitial pneumopathy 37 (33) 23 (29) 14 (45) 0.099
Lobar+Interstitial 2 (2) 1 (1) 1 (3) 0.482
P. Jiroveci 14 (13) 9 (11) 5 (16) 0.541
Unspecified 25 (22) 15 (19) 10 (32) 0.209
Bronchiolitis 18 (16) 14 (17.5) 4 (13) 0.580
Bronchiectasis 3 (3) 2 (2.5) 1 (3) 0.832
Other severe bacterial infections 19 (17) 9 (11) 10 (32) 0.023
Sepsis 11 (9) 6 (7.5) 5 (16) 0.291
Meningitis 3 (3) 0 (0) 3 (10) 0.023
Skin and lymph node abscesses 4 (4) 3 (4) 1 (3) 1.00
Omphalitis 1 (1) 0 (0) 1 (3) 0.290
Otitis 20 (18) 14 (17.5) 6 (3) 1.00
Systemic viral infections 31 (28) 20 (25) 11 (35.5) 0.356
CMV 18 (16) 12 (15) 6 (19) 0.776
EBV 7 (6) 4 (5) 3 (10) 0.411
HSV1/2 5 (4.5) 3 (4) 2 (6) 0.626
Adenovirus 1 (1) 1 (1) 0 (0) 1.00
Opportunistic infections 25 (22) 17 (21) 8 (26) 0.802
Candidiasis 19 (17) 12 (15) 7 (23) 0.414
Disseminated fungal infection 6 (5) 5 (6) 1 (3) 0.670
BCG infection 5 (4.5) 4 (5) 1 (3) 1.00
Mycobacterium tuberculosis 1 (1) 0 (0) 1 (3) 0.290
OS 19 (18) 14 (17) 5 (16) 1.00
ME* 15 (28) 12 (33) 3 (18) 0.236
Omenn-like +ME* 3 (6) 3 (8) 0 (0) 0.293
Gastrointestinal features 54 (49) 35 (44) 19 (61) 0.201
Chronic diarrhea 27 (24) 21 (26) 6 (19) 0.466
Failure to thrive 39 (35) 21 (26) 18 (58) 0.004
Villous atrophy 6 (5) 1 (1) 5 (16) 0.008
Protein loss entheropathy 6 (5) 2 (2.5) 4 (13) 0.057
Eczema 27 (24) 17 (21) 10 (32) 0.467
Transient or treatable 4 (4) 3 (4) 1 (3) 1.00
Untreatable 10 (9) 8 (10) 2 (6) 0.720
Erythrodermia 13 (12) 6 (7.5) 7 (23) 0.050
Immune dysregulation 25 (22) 15 (19) 13 (42) 0.028
Autoimmune cytopenia 13 (13) 8 (10) 6 (19) 0.193
Granuloma 3 (2) 1 (1) 2 (6) 0.201
Alopecia/ectodermal dystrophy 5() 1(1) 4 (13) 0.204
Vasculitis 2 (2) 2 (2.5) 0 (0) 1.00
Thyroiditis 2 (2) 1 (1) 1 (3) 0.497
Hematological disorders 17 (15) 12 (15) 5 (16) 1.00
HLH 4 (4) 3 (4) 1 (3) 1.00
Lymphadenopathy 13 (12) 8 (10) 5 (16) 0.516
Lymphoproliferative disorders 2 (2) 1 (1) 1 (3) 0.497
Organomegaly 54 (48.5) 36 (45) 18 (58) 0.395
(Continued)
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TABLE 2 | Continued
Feature Overall (%) Non syndromic (%) Syndromic (%) P-value
No = 111 No = 80 No = 31
Liver enlargement 31 (28) 22 (27.5) 9 (29) 0 1.00
Spleen enlargement 23 (20.5) 14 (17) 9 (29) 0.301
Intensive care unit admission 9 (8) 7 (9) 2 (6) 0.690
CMV, cytomegalovirus; EBV, epstein barr virus; HSV, Herpes simplex virus; BCG, Bacillus Calmette Guerin; OS, Omenn syndrome; ME, Maternal Engraftment; HLH,
Haemophagocytic Lymphohistiocytosis.
Bold indicates statistical significance (P < 0.05).
*Frequency was calculated as percentage of patients tested for ME (n = 53; syndromic n = 17).
and autoimmune cytopenia, more frequent in atypical SCIDs
(Supplemental Table S1).
As detailed in Table 3, extra-immunological signs were
identified in 31 subjects, and mainly included birth defects,
such as musculoskeletal or genitourinary tract malformation,
or neurological manifestations. Neurological manifestations
included both sensory or motor deficits, and were unlikely to
be caused by infections, since only two patients suffered from
a severe invasive infection of CNS. EBV and CMV-DNA levels
were evaluated in peripheral blood through real-time polymerase
chain reaction (PCR) in 15 out of 19 subjects. Five of them had a
systemic CMV infection (CMV viremia). The age at presentation
suggested a postnatal acquisition of CMV rather than congenital
infection, even though, in most of the cases, we couldn’t rule out
a congenital infection, since samples obtained within 3 weeks
of age were not available. In one case, PCR analysis of dried
blood samples on the Guthrie card was performed to exclude a
congenital infection. In 2 subjects, PCR on peripheral blood was
positive for EBV or adenovirus, respectively, but cerebrospinal
fluid (CSF) liquor examination was negative. Eleven patients had
dysmorphic features and one had situs viscerum inversus.
Twenty-one percent of the subjects had anemia, which was
severe (Hb < 8 g/l) in 40% of them (9/23). Neutropenia was
observed in 16.5% of the patients (n = 15), with a mean
absolute neutrophil count of 646.8 ± 401.6 cells/mm3 (range
0–1447 cell/mm3). Bilinear (neutropenia + anemia) or trilinear
cytopenias (neutropenia + anemia + thrombocytopenia) were
detected in 4 and 2 patients, respectively. More than half of
subjects had eosinophilia and in 60% of the cases, it was not
associated with OS. However, eosinophilia was more severe (>
2,000 cell/mm3) in patients with OS/ME. Thrombocytosis was
observed in 48.5% of the patients (range 452.000–1.092.000
cells/mm3). Multivariate analysis showed an interdependency
between thrombocytosis, infection and inflammatory skin
disorders (eczema) (data not shown). One patient with IL2RG
defect developed a lymphoproliferative disorder not EBV-
related, while a patient carrying DLREC1A biallelic genetic
alterations developed an EBV-related large B-cell lymphoma
of nasopahrynx. The same subject also developed a primary
cutaneous CD8+ acral T-cell lymphoma.
We performed Fisher’s exact test to compare the prevalence
of all phenotypic variables in the subgroups of the cohort.
Non lymphopenic patients showed a higher prevalence of
hematological disorders compared to lymphopenic patients
TABLE 3 | Extra-immunological features of the SCID cohort.
Features n. of subjects (%)
Overall 31 (28)
Birth defects
Facial dysmorphism 11 (35)
Skeletal anomalies 7 (22.5)
Genitourinary anomalies 4 (13)
Gastrointestinal anomalies 2 (6)
Situs Viscerum Inversus 1 (3)
Congenital heart disease
Conotruncal defects 1 (3)
Septal defects 3 (10)
Neurological disorders
Microcephaly 7 (23)
Unexplained cerebral atrophy 1 (3)
Sensorineural hearing loss 1 (3)
Developmental delay 9 (29)
Epilepsy 1 (3)
Hypotonia 3 (10)
Flaccid tetraparesis 1 (3)
Palpebral ptosis 1 (3)
Other 2 (6)
(p= 0.046). DD was not different between these 2 groups.
Bronchiectasis were more frequent in patients with early onset
(AO ≤ 9 months) compared to late onset forms (p= 0.011).
We next performed multivariate analysis to obtain
information about the interdependency between the observed
variables. In particular, patients were stratified according to
age at onset (before or after 9 months of age), outcome (alive
or dead), diagnostic delay (more or less than 3 months),
syndromic or non syndromic patients and immunological
features (lymphopenic or not lymphopenic, typical or atypical).
With an eigenvalue > 3, varimax rotation yielded a 3-factor
model where a few variables are correlated one to each other. As
shown in Figure 2, we found that patients with AO > 9 months
had additional clusters of disorders, as compared to patients
with AO ≤ 9 months, assuming as eigenvalue cut-off of 3: the
first characterized by benign/malignant lymphoproliferation,
hematological disorders and granuloma (LPD-cluster); the
second characterized by immunedysregulation associated with
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FIGURE 2 | Multivariate analysis in SCID patients according to age at onset. (A) AO > 9 mo, (B) AO ≤ 9 mo. All components with eigenvalues under 3 were dropped.
Factor loadings in the analysis are illustrated in the right part of the panel. Clusters of variables positively correlated are indicated. LPD-cluster, lymphoproliferative
disorder-cluster; IDP-cluster, Immuno-dysregulation and pulmonary infection-cluster.
pulmonary infections (IDP-cluster). The analysis did not reveal
any significant difference in phenotypic presentation clusters in
patients stratified according to the other parameters.
Genotype Characterization
A genetic diagnosis was obtained in 70% (77/111) of all
the patients and in 87.5% (77/88) of the children who
underwent molecular investigation. Most of cases (71.5%) were
studied through a traditional candidate gene approach using
Sanger direct sequencing. Genes were selected based on the
immunophenotypic classification, the gender, clinical features
and inheritance pattern. In the 28.5% of the cases, a genetic
diagnosis was obtained using high-throughput sequencing
(HTS). This technique was introduced in most of the Centers in
the last decade. In 2 patients with a complete DiGeorge (cDGS)
clinical phenotype (2.5%, 2/77) CGH-array analysis revealed a
typical 22q11.2 deletion and a 14q deletion, respectively.
CSD was the most frequent genetic cause, accounting for 35%
of the cases (Figure 3A), while VDJ abnormalities and DNA-
RD accounted for the 31% of the cases. Twenty patients (26%)
had alterations in RAG1/2 genes and 4 (5%) had defects in the
DNA repair machinery (DCLRE1C, Cernunnos/XLF, LIG4).ADA
deficiency was diagnosed in 15 subjects (7 of them being of other
geographic origin). Six percent of the patients had a SCID caused
by a primary thymic developmental disorder (PAX1, FOXN1,
cDGS). Rare genetic causes, as PAX1 and TTC7A deficiencies
were identified through HTS.
Within the group of SCID patients who received a molecular
characterization, the rate of a positive molecular diagnosis was
86% among patients of Italian origin (57 out of 66 patients)
and 91% (20 out of 22 patients) among patients of different
geographic areas.
Immunological Characterization at
Diagnosis
Most of the patients (75%) were lymphopenic at the diagnosis,
while 24 patients (24.2%) had normal or even increased
lymphocyte counts, as compared to age-matched reference
values. Nine out of 19 OS patients were lymphopenic while 7
had increased lymphocyte counts. Most of the non lymphopenic
patients had CSD or VDJ disorders (31 or 35%, respectively) and
50% of the subjects with DNA-RDs had a normal lymphocyte
count. None ofMD patients had a near normal lymphocyte count
(Figure 3B). Three non lymphopenic patients had ME.
As shown in the Figure 3C, the majority of the patients
(60%) had a T− form, 50% of whom being B−. Within the
T−B+ subgroup, NK cells were absent in approximately 50%
of the patients. Among patients with T−B− SCID, 41% were
also NK− negative.
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FIGURE 3 | Genetic causes and immunophenotype of the cohort. (A) Histogram distribution of the genetic defects underlying SCID. The pathogenic mechanisms
implicated are indicated. ADA, adenosine deaminase; IL2RG, interleukin 2 receptor gamma; JAK3, Janus kinase 3; IL7R, interleukin 2 receptor; RAG,
recombinase-activating genes; LIG4, DNA Ligase IV; FOXN1, Forkhead Box N1; PAX1, Paired Box Gene 1; TTC7A, Tetratricopeptide Repeat Domain-Containing
Protein 7A; RFXANK, Regulatory Factor X, Ankyrin Repeat-Containing; CIITA, Class II Transactivator; RFX5, Regulatory Factor X; IKBA, NFKB inhibitor alpha.
(B) Proportion of lymphopenic or non lymphopenic patients according to the pathogenic group. (C) Distribution of the cohort according the immunophenotype,
expressed as percentage values.
We next evaluated the immunophenotype in the group of
35 patients with atypical SCID of known genetic basis. All
patients but 3 (2 with FOXN1 and 1 with RFXANK deficiency)
had an atypical immunophenotype, as compared to what
expected on the basis of the genotype. As shown in Table 4,
the majority of atypical phenotypes were noted in 12 patients
in the subgroup of the cytokine signaling defects (IL2RG or
JAK3). In this group, the presence of T cells was potentially
explained by OS/ME only in 2 cases. In addition, all the 8 IL2RG
deficient patients without clinical manifestations of OS/ME also
had normal/elevated NK cells. Interestingly, the mutation in
the IL2RG gene was hypomorphic in one patient, while the
remaining subjects carried severe mutations. Only 5 patients
(11%) among typical SCID had an unpredicted phenotype as
compared to genotype. More detailed site-specific mutations,
with hypomorphic or severe effect, in the group of atypical
subjects are listed in Table 5.
OS or ME were identified in 7 out of 13 patients with
RAG1/2 defects, and in an individual patient carrying a defect
in Cernunnos/XLF.
We, finally, performed an intrafamilial comparison of the
immunological and clinical phenotype in 4 families with 2
affected siblings. As shown in Table 6, in 3 pedigrees we
observed a discordant immunological phenotype. In particular,
differently from their siblings, patients A1 and B2 had low
T cells. Furthermore, NK cells were low in A1, but normal
in his brother. Patient C1 had a Tlow SCID, with reduced
but detectable CD3+ and CD8+ cells and a severe CD4+
lymphocytopenia, while his brother had a T−SCID with severe
reduction of both CD4+ and CD8+ cells. Of note, ME, which
could have explained the variability in the CD8 count, was
ruled out in patient C1 by STR analysis. Patient A1 developed
severe protracted diarrhea and hypoproteinemia at 1 month
of age followed by bronchiolitis at 1.5 month of age. He was
hospitalized because of failure to thrive at the age of 4 months.
His younger brother (patient A2) was diagnosed with SCID at
the age of 3.5 months because of a positive family history and
clinical manifestations of OS (erythroderma, lymphadenopathy,
spleen enlargement, eosinophilia, increased number of activated
T-cells, reduced proliferative response to mitogen). RFLP ruled
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TABLE 4 | SCID patients with known gene defect and discordant
immunophenotype.
Gene defect Expected
phenotype
Observed
phenotype
No. % of the
genotype
subgroup
OS/ME
Typical 5
IL2RG T−B+NK− T−B+NK+ 1 12.5 0/0
T−BlowNK+ 1 12.5 0/0
RAG1/2 T−B+NK+ T−B−NK+ 1 14 0/1
ADA T−B−NK− T−B+NK+ 1 8 0/0
MHC class II-D* T+B+NK+ T−BlowNK+ 1 100 0/0
Atypical 31
IL2RG T−B+NK− TlowB+NK+ 6 31.5 0/1
T+B+NK+ 3 16 1/1
TlowB+NKlow 1 5 0/0
JAK3 T−B+NK− TlowB+NK− 1 14 0/0
TlowB+NK+ 1 14 0/0
RAG1/2 T−B+NK+ T+B−NK+ 7 35 3/0
TlowB+NK− 2 10 1/1
T+B+NK+ 3 15 1/0
TlowB−NK− 1 5 1/0
MHC class II-D* T+B+NK+ TlowB+NK+ 3 75 0/0
IKBA T+B+NK+ T+B+NK− 1 100 0/0
Cernunnos T−B−NK+ TlowB−NK+ 1 100 1/0
RFX5 T+B+NK+ TlowB+NK? 1 100 0/0
DCLER1C T−B−NK+ T+BlowNK− 1 100 0/0
LIG4 T−B−NK+ TlowBlowNK+ 1 50 0/0
CIITA T−B+NK+ T+B+NK+ 1 100 0/0
Del14 T−B+NK+ TlowB−NK+ 1 100 0/0
*Major histocompatibility complex (MHC) class II Deficiency. OS, Omenn syndrome; ME,
Maternal Engraftment.
out ME. Patient C1 developed Pneumocistis Jiroveci pneumonia
at the age of 3 months and died of severe respiratory failure
and pulmonary arterial hypertension, while his asymptomatic
brother was diagnosed because of the positive familial history.
The clinical phenotype of the two of FOXN1 siblings has been
previously reported (19). The outcome was also discordant in 2
pairs, even though this was likely due to difference in DD rather
than to the different immunological phenotype.
Pre-treatment Mortality
The mortality rate before any definitive treatment (HSCT or GT)
was 14.4% (16 cases). Seven patients died of severe infections,
while OS or HLH were the cause of death in 3 further
subjects. Multi-organ failure, pulmonary hypertension or severe
electrolyte disorders were the causes of death in the remaining
6 patients.
Pre-treatment mortality was higher in patients with atypical
vs. typical SCIDs (13/53 vs. 3/46, p = 0.0263) and in syndromic
vs. non-syndromic SCID patients (9/31, 29 vs. 7/80, 9%,
respectively; p = 0.0188). All the subjects who died before
definitive treatment had an AO <underline<> 9 months. No
association was found between DD > 3 months (n = 5)
and pre-treatment mortality. We performed a multivariate
analysis to evaluate the phenotypic cluster of signs in patients
who died before treatment, a multivariate analysis. In atypical
patients with poor prognosis, the clinical phenotype was mainly
characterized by 4 clusters of symptoms, represented by a skin-
blood cluster, 2 PID-clusters, and growth-development cluster
(Supplemental Figure S2). The analysis was not performed in
typical SCID due to the limited number of subjects.
DISCUSSION
The main aim of the IPINET study was to better define the
natural history of different forms of SCIDs in order to improve
the clinical management and increase the awareness of physicians
on these often under recognized disorders. In this regard, retro-
prospective studies on large cohorts of patients represent a
unique tool to obtain reliable data on the natural history of these
diseases (20).
The present study represents the first description of the
clinical, immunologic and molecular features of a multi-centric
cohort of patients affected with either typical or atypical SCIDs,
followed within the IPINET network over a period of observation
of 3 decades. In particular, the study was focused on presenting
signs and natural history before HSCT or GT. As expected,
the majority of the patients were diagnosed in the last decade
of observation, thanks to improved awareness and broader
availability of powerful genetic tests (16). In addition, in the
last decade of observation, along with a progressive increase
typical forms with very low AO, we also observed a significant
number of the cases with a AO > 9 months. This may be
explained by the recent increased awareness of atypical forms,
that are often characterized by a later onset of the disease (21,
22). It is possible that the majority of these novel conditions
were previously considered as “other not well-characterized”
PIDs, or even misdiagnosed, since their presentation was often
characterized by mild signs of immune dysfunction (23).
In a significant number of subjects (28% of the cohort), the
SCID phenotype was part of a complex syndromic phenotype
with multisystem anomalies, including multiple birth defects
or neurological manifestations. Manifestations of immune
dysregulation, mainly presenting as autoimmune cytopenia
or ectodermal disorders, were observed more frequently
in syndromic than in non-syndromic group (42 vs. 19%).
Differently from what previously reported in other cohorts of
syndromic SCID patients (24), we observed the same prevalence
of severe infections in syndromic and non-syndromic patients.
As expected, active and severe infections represent the most
common cause of death in all the different categories of
SCID patients. It is remarkable that 8% of children, previously
considered “healthy,” presented with a single rapidly-progressive
severe lung infection requiring ICU admission. Even if other
groups have previously reported that 9% of all the PIDs patients
require ICU admission during the follow-up (25), in this study we
showed for the first time that admission to the ICU may prompt
the suspicion of SCID. This observation should pave the way for
future studies aimed at identifying the prevalence of SCID in
children admitted in ICUs.
Frontiers in Immunology | www.frontiersin.org 10 August 2019 | Volume 10 | Article 1908
Cirillo et al. Severe Combined Immunodeficiency Italian Cohort
TABLE 5 | Genetic mutations in atypical SCID due to cytokine signaling disorders.
Gene ID Pt Nucleotide change Status Predicted change Hypomorphic Severe
IL2RG 9 c.676C>T Hemyzygous R226C - +
24a c.202G>A Hemyzygous E68K + -
30 c.548T>C Hemyzygous L183C - +
68 c.334A>C Hemyzygous T112P + -
73 c.684C>T Hemyzygous R224W - +
79 c.684C>T Hemyzygous R224W - +
80 c.485T>G Hemyzygous L162R - +
83b c.981_1001del Hemyzygous R328E334del - +
90 c.854G>A Hemyzygous Aberrant splice - +
105 c.741insG Hemyzygous S248fs - +
JAK3 11 c.1208G>A Homozygous R403H + -
111 c.1796T>G Compound V599G + -
c.2125T>A Heterozygous W709R + -
aOmenn-like syndrome + Maternal Engraftment.
bMaternal Engraftment.
TABLE 6 | Clinical and immunological features of SCID siblings.
Patient
ID
AO AD DD Gene Onset sign OS ALC
cells/µL
CD3+
cells/µL
CD4+
cells/µL
CD8+
cells/µL
CD19+
cells/µL
CD56+
cells/µL
Immunophenotype Outcome Cause of
deaths
A1 1 4 3 Unknown Chronic diarrhea - 1100a 972a 720a 306a 18a 616a TlowB−NK+ dead Systemic
viral
infection
A2 0.5 3.5 3 Unknown Erythroderma + 22255 9258 4206 5786 89a 3116 T+BlowNK+ dead OS
B1 2 6 4 FOXN1 Eczema + 5392 2006 1065 439 3950 1442 T+B+NK+ dead Pneumonia
B2 1 1 0 FOXN1 Eczema + 2688 753a 645a 215a 962 650 TlowB+NK+ alive
C1 3 8 5 IL2RG P. Jiroveci
pneumonia
- 5528 719a 55a 685a 4765 NA TlowB+ dead PH
C2 12 12 0 IL2RG Asymptomatic - 931a 19a 2a 9a 847 7.4a T−B+NK− alive
D1 3 5 2 JAK3 Chronic diarrhea - 1824a 62a 40a 18a 1621 11a T−B+NK− alive
D2 2 2 0 JAK3 Asymptomatic - 3926 12a 0a 1a 3299 10a T−B+NK− alive
a
< normal age range value; ALC, Absolute Lymphocyte count; NA, not available; OS, Omenn syndrome; PH, pulmonary arterial hypertension.
A peculiar observation in this cohort is the high
proportion of patients with platelet count abnormalities,
along with anemia, which were observed in almost
half of the subjects. Differently from what expected,
thrombocytosis was more frequent than thrombocytopenia
and multivariate analysis demonstrated an interdependency
of thrombocytosis with infections and inflammatory skin
conditions as eczema.
Patients affected with DNA-RDs, typically, also show extra-
hematopoietic alterations (26), which may predominate on
clinical signs of immunodeficiency and lead to DD. In these
subjects, the definition of the functional and molecular defect is
essential for choosing the best therapeutic strategy. Due to the
systemic nature of these disorders, the use of reduced intensity
conditioning regimens is crucial to reduce mortality, systemic
morbidity and long-term effects on other somatic cells harboring
the genetic defect due to the effect of chemotherapy or ionizing
radiation (27–30). The high mortality rate, observed by other
groups, may be potentially explained either by the higher DD or
by the increased DNA vulnerability (31, 32).
Genetic studies with traditional Sanger sequencing, HTS, or
CGH-array were performed on 79% of the 111 patients. The
overall diagnostic rate of the analyzed patients was 87.5%, and
it was comparable to other cohorts (32, 33). No difference
was observed in the rate of definitive genetic diagnosis among
subjects of different geographic areas. Even though cytokine
signaling defects were the most common group of genetic
disorders in this study, the frequency of defects in genes encoding
for proteins involved in the DNA recombination pathways
(RAG1, RAG2) was similar to that of IL2RG gene defects, and
accounted for the 26% of the whole cohort. This prevalence
is higher than those recently reported in 2 prospective SCID
studies performed in USA and in Asia (5, 34, 35). Although this
observation may reflect a real difference in disease epidemiology,
it should be noted that the rate of consanguineous marriages,
can be higher in certain Italian geographic areas compared to
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other countries such as USA. Moreover, a founder effect may be
a possible explanation for the high frequency of some specific
mutations, such as the R225Xmutation in FOXN1 gene observed
in the Acierno population (36).
In our study, SCIDs due to intrinsic thymic abnormalities,
as cDGS, FOXN1 defects and the recently described PAX1
defect (36–38), accounted for 6% of the cases. This subgroup
of SCIDs patients deserves careful consideration, since the
traditional HSCT approach may be ineffective, or scarcely
effective, and further therapies, as thymus transplantation should
be considered (39–41).
Finally, the introduction into the clinical setting
of the HTS technologies allowed the identification of
a variety of very rare genetic forms, such as TTC7A,
IKBA, RFXANK, or CIITA defects, that, otherwise would
not have been, recognized. This observation further
support a role for these technologies together with
proper functional validation, as powerful diagnostic tool
for PIDs.
Of note, about 25% of the subjects were not
lymphopenic. It is noteworthy that OS/ME developed both
in patients with normal/high age-matched lymphocytes
count and in lymphopenic subjects, thus implying
that also lymphopenic patients should be monitored
for OS.
During the study period we identified a significant number
of subjects with atypical forms, not fulfilling ESID diagnostic
criteria. Among the group of atypical SCIDs with a known
genetic cause, almost the totality of the subjects had an
immunophenotype discordant to what expected on the basis of
the genotype. In the group of subjects with RAG1/2 defect, the
presence of T cells was potentially explained by hypomorphic
mutations and/or OS, or ME. Conversely, the atypical phenotype
was associated with OS/ME only in 2 subjects with cytokine
signaling defects. In particular, we observed that a significant
proportion (about 40%) of IL2RG-mutated patients had near
normal or low but detectable T-cell number. Hypomorphic
mutations in several genes including DCLRE1C, LIG4, RAG1,
and JAK3 genes have been identified in patients with atypical
SCID (42–46). To date, few patients harboring hypomorphic
mutations in the IL2RG gene, responsible for an atypical
phenotype, have also been described, the majority of them
carrying the c.664C>T mutation (47, 48). In our group of
IL2RG atypical SCID, 2 different hypormophic mutations, not
previously reported in other case series, were identified in
2 unrelated families. Interestingly, one of them, harboring
the p.E68K mutation, exhibited the coexistence of omenn-like
disorder and ME, thus explaining the TlowB+NK+ phenotype. In
the remaining atypical IL2RG deficient patients, the mutations
were severe, similarly to what previously reported by Mella et al.
(49). In this latter group, further mechanisms, such as somatic
cell gene reversion (50), mosaicisms, or a generic influence of
environmental factors or of other gene modifiers may underlie
the biological basis of the atypical phenotype. Interestingly,
somatic mutations, can restore the wild-type sequence of the
SCID-associated gene in a subset of lymphocytes, or introduce
second-site mutations that permit the expression of partially
functioning proteins (1). Similar hypotheses may also help to
explain intrafamilial variability.
As for the two JAK3-mutated patients, they carried previously
described hypomorphic mutations (46, 51). Functional
immunological and genetic studies are mandatory to recognize
such patients, since most of these patients had near normal total
CD4 and/or CD8 counts.
Assuming a disease prevalence, based on the NBS available
data, comprised between 1:40,000 and 1:58,000 (3), we would
have expected about 285–415 cases of SCIDs over the 3 decades
of observation (16,614,332 recorded live births). Thus, our
data clearly indicate that, even though, it is possible that a
few cases have been missed due to the voluntary participation
to the study, the majority of the patients with SCID may
have remained undiagnosed. In particular, we estimate that we
have captured approximately only the 27–39% of all expected
cases. However, a real estimate of the frequency of SCID in
Italy is not possible. This clearly indicates that a nationwide
NBS program is strictly necessary, and emphasizes the need to
improve awareness of the broad phenotypic spectrum of SCID
in order to facilitate diagnosis of cases with atypical signs of the
disease (2).
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